Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study.
Ahmad A SherbiniJames Martin GwinnuttKimmie L Hyrichnull nullSuzanne M M VerstappenPublished in: Rheumatology (Oxford, England) (2022)
AEs were common among patients over the first year of MTX, although most were not serious. Knowledge of the rates and factors associated with AE occurrence are valuable when communicating risks prior to commencing MTX. This can help patients make informed decisions whether to start MTX, potentially increasing adherence to treatment.